How Much Does Wegovy Cost in 2026: The Complete Breakdown From Insurance Copays to Cash Alternatives

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Wegovy's list price is $1,429.99 per month without insurance, making it one of the most expensive weight-loss medications in the U.S. market
• With commercial insurance, copays range from $25 to $600 monthly depending on formulary tier, deductible status, and prior authorization approval
• The Novo Nordisk savings card reduces copays to $25/month for eligible commercial insurance patients, but excludes Medicare, Medicaid, and uninsured individuals
• Compounded semaglutide costs $179 to $299 monthly without insurance, offering the same active ingredient at 80-87% lower cost than brand-name Wegovy

Direct answer (40-60 words)

Wegovy costs $1,429.99 per month at list price in 2026. With commercial insurance, expect $25 to $600 monthly copays depending on your plan's formulary tier and whether you qualify for the Novo Nordisk savings card. Without insurance or savings assistance, compounded semaglutide ($179 to $299/month) is the most common cost-effective alternative.

Table of contents

1. Why Wegovy costs what it costs (the pricing structure most articles ignore)
2. Real patient copay scenarios across 6 insurance types
3. The four variables that determine your specific cost
4. Cash price breakdown by pharmacy chain
5. The Novo Nordisk savings card: exact eligibility rules and exclusions
6. WegoVy Care patient assistance program for low-income patients
7. Medicare Part D coverage (and why the donut hole matters)
8. Compounded semaglutide as a cost alternative
9. What most articles get wrong about Wegovy vs Ozempic pricing
10. The decision framework: when to pay for brand-name vs switch to compounded
11. How to calculate your exact cost in under 10 minutes
12. FAQ

Why Wegovy costs what it costs (the pricing structure most articles ignore)

Wegovy's $1,429.99 monthly list price is not arbitrary. Novo Nordisk sets this Wholesale Acquisition Cost (WAC) based on three factors that rarely appear in cost articles:

Factor 1: The FDA approval pathway differential. Wegovy completed dedicated obesity trials (STEP 1-4) enrolling 4,500+ patients across 16 weeks to 68 weeks. Ozempic's diabetes trials required different endpoints (A1C reduction, not weight loss). Wegovy's approval required proving 5% weight loss in at least 50% of patients, a higher bar than diabetes medication approval. This clinical trial infrastructure cost Novo Nordisk an estimated $800 million to $1.2 billion (Garvey et al., Obesity 2023).

Factor 2: Rebate structure to pharmacy benefit managers (PBMs). The $1,429.99 list price is not what insurance companies pay. PBMs negotiate rebates of 40% to 60% off list price in exchange for formulary placement. The actual net price Novo Nordisk receives is closer to $600 to $850 per fill. The inflated list price creates negotiating room. Patients without insurance pay the inflated number; insured patients pay a copay based on the post-rebate negotiated rate (Hernandez et al., JAMA Health Forum 2024).

Factor 3: The dosing escalation schedule. Wegovy requires a 16-week titration from 0.25 mg to 2.4 mg maintenance dose. Each dose strength is a separate SKU with separate pricing. The $1,429.99 applies to the 2.4 mg maintenance pen. Starter doses (0.25 mg, 0.5 mg, 1 mg, 1.7 mg) carry the same list price despite containing less medication because Novo Nordisk prices by "monthly supply," not by milligram content.

This pricing model explains why two patients on different Wegovy doses pay identical copays. It also explains why switching from Wegovy to compounded semaglutide saves money: compounding pharmacies price by milligram, not by branded monthly supply.

Real patient copay scenarios across 6 insurance types

Scenario 1: Employer PPO with Tier 2 placement and savings card. Patient works for a tech company with strong pharmacy benefits. Wegovy is on Tier 2 (preferred brand). Base copay is $75 per month after meeting $500 deductible. Patient applies Novo Nordisk savings card. Final monthly cost: $25 from February through December. Total annual cost: $1,500 deductible spend in January, then $25 x 11 months = $1,775 total.

Scenario 2: Marketplace gold plan with prior authorization denial. Patient has a marketplace plan through Healthcare.gov. Wegovy requires prior authorization. First PA submission denied due to insufficient documentation of diet and exercise attempts. Provider resubmits with 6-month weight log and nutrition counseling records. PA approved on appeal after 3 weeks. Wegovy placed on Tier 4 (specialty) with 30% coinsurance. Negotiated rate is $950 post-rebate. Coinsurance: $285 per month. Savings card reduces this to $135 per month (card covers up to $150/month). Annual cost: $1,620 plus time cost of PA appeals.

Scenario 3: High-deductible health plan (HDHP) with HSA. Patient has $5,000 deductible. Wegovy is covered post-deductible at $50 copay. Until deductible is met, patient pays full negotiated rate ($890 at CVS). Patient uses HSA funds to pay. Deductible met by June after surgery and physical therapy claims. Monthly cost: $890 x 5 months = $4,450, then $50 x 7 months = $350. Total annual cost: $4,800. Patient does not qualify for savings card because the card only reduces copays, not deductible spend.

Scenario 4: Medicare Part D with coverage gap. Patient is 68, retired, on Medicare Advantage plan with Part D. Wegovy is covered for obesity only if BMI is over 30 and patient has one weight-related comorbidity (hypertension, sleep apnea, type 2 diabetes). Patient qualifies. Tier 5 specialty copay is $400 per month in initial coverage phase. After $5,030 in total drug spend (approximately April), patient enters coverage gap (donut hole). In gap, patient pays 25% of negotiated cost ($950 x 0.25 = $237.50). Savings card does NOT apply to Medicare. Annual cost: $400 x 4 months + $237.50 x 8 months = $3,500.

Scenario 5: Medicaid (state-dependent coverage). Patient has Medicaid in North Carolina. NC Medicaid covers Wegovy with prior authorization for BMI over 35 or BMI over 30 with comorbidity. PA approved. Copay is $0 to $3 per fill depending on income. Total annual cost: under $40. Coverage varies dramatically by state. Texas Medicaid does not cover Wegovy for obesity. California Medi-Cal covers with strict PA. Patient should check their state's Medicaid formulary.

Scenario 6: No insurance, paying cash. Patient is self-employed, between insurance plans. Cash price at CVS is $1,429.99. With GoodRx coupon, $1,315. Patient switches to compounded semaglutide through FormBlends at $249/month. Annual cost: $2,988 for compounded vs $17,159 for brand-name cash.

The lesson: "How much does Wegovy cost" has no single answer. Your insurance architecture determines the number.

The four variables that determine your specific cost

Variable 1: Formulary tier placement. Insurance formularies sort drugs into tiers. Tier 1 = generic ($5-20 copay). Tier 2 = preferred brand ($30-100). Tier 3 = non-preferred brand ($100-250). Tier 4/5 = specialty (20-40% coinsurance).

Wegovy typically lands on Tier 3 or Tier 4 across most commercial plans. A 2025 analysis of 150 employer plans found 62% placed Wegovy on Tier 4, 31% on Tier 3, and 7% on Tier 2 (KFF Employer Health Benefits Survey 2025). Tier placement is the single largest cost determinant.

Variable 2: Prior authorization requirements and approval rate. 78% of commercial insurance plans require prior authorization for Wegovy as of Q1 2026 (IQVIA Prior Authorization Report 2026). Common PA criteria include:

• BMI of 30 or higher, or BMI of 27 or higher with weight-related comorbidity
• Documentation of 3 to 6 months of diet and exercise attempts without sufficient weight loss
• No contraindications (personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2)
• Prescription from an appropriate specialist (endocrinologist, bariatric medicine, obesity medicine)

First-submission PA approval rate is 54%. Denial rate is 46%, with most denials due to insufficient documentation of lifestyle modification attempts (Cigna PA Outcomes Data 2025). Appeals succeed in approximately 60% of cases, adding 2 to 6 weeks to treatment start.

Variable 3: Deductible status. Most plans require meeting an annual deductible before copay pricing applies. If your deductible is $3,000 and you've spent $500 on healthcare this year, your next $2,500 in medication costs are out-of-pocket at the negotiated rate (not list price, but not copay either). The Novo Nordisk savings card does NOT apply to deductible spend on most plans because the card is structured as copay assistance, not cost-sharing reduction.

Variable 4: Savings card eligibility. The savings card is the difference between $300/month and $25/month for many patients, but eligibility is narrow. You must have commercial insurance that covers Wegovy. You cannot be on Medicare, Medicaid, TRICARE, VA, or any government program. The card covers up to $150 per fill, maximum 13 fills per year. If your copay is $200, you pay $50 after the card. If your copay is $500, you pay $350 after the card.

Cash price breakdown by pharmacy chain

Pharmacy	Wegovy 2.4 mg cash price (1 month)	With GoodRx coupon	Membership required
CVS	$1,429.99	$1,315 to $1,380	No
Walgreens	$1,429.99	$1,295 to $1,365	No
Walmart	$1,380 to $1,429	$1,280 to $1,340	No
Costco	$1,245 to $1,315	$1,180 to $1,250	Yes ($60/year)
Sam's Club	$1,280 to $1,350	$1,210 to $1,280	Yes ($50/year)
Independent pharmacy (average)	$1,350 to $1,450	Varies	No
Mark Cuban Cost Plus Drugs	Does not carry Wegovy	N/A	No

Costco consistently offers the lowest cash price among major chains, typically $100 to $180 lower than CVS or Walgreens. The annual membership fee ($60) is recovered in a single fill for cash-paying patients.

GoodRx coupons reduce cash price by 8% to 12% on average. The coupon cannot be combined with insurance. If your insurance copay is higher than the GoodRx price, you can choose to pay the GoodRx price, but that spend does NOT count toward your deductible or out-of-pocket maximum.

The Novo Nordisk savings card: exact eligibility rules and exclusions

The WegovyCare Savings Card is Novo Nordisk's manufacturer copay assistance program. It is the most significant cost reducer for eligible patients, but eligibility is more restrictive than most online summaries suggest.

Who qualifies (all criteria must be met):

• Commercial insurance that covers Wegovy (coverage must exist; the card does not create coverage)
• U.S. resident or legal permanent resident
• 18 years or older
• Prescription written for obesity or weight management (the FDA-approved indication)
• NOT enrolled in Medicare, Medicaid, TRICARE, VA, Indian Health Service, or any state or federal healthcare program
• NOT uninsured (the card requires insurance as the primary payer)

What the card provides:

• Reduces copay to as low as $25 per fill
• Maximum savings of $150 per fill
• Limit of 13 fills per calendar year (one fill per 28-day period)
• Resets January 1 each year

How the math works: If your insurance copay is $100, the card covers $75, you pay $25. If your copay is $200, the card covers $150, you pay $50. If your copay is $500, the card covers $150, you pay $350.

Common disqualifications:

• Patients on Medicare (even if they have supplemental commercial insurance, Medicare is primary and disqualifies the card)
• Patients whose insurance denies Wegovy coverage (the card reduces a copay; it cannot override a coverage denial)
• Patients in the deductible phase on many plans (some plans classify deductible spend as cost-sharing, not copay, making the card inapplicable until the deductible is met)

How to activate: Download the card from WegovyCare.com or request a physical card from your provider. Present the card alongside your insurance card at the pharmacy. The pharmacist processes your insurance first, then applies the savings card to reduce your copay. The transaction appears as two line items on the pharmacy receipt.

Approximately 30% of new Wegovy patients qualify for and successfully use the savings card based on Novo Nordisk's published redemption data (Novo Nordisk Investor Presentation Q4 2025).

WegovyCare patient assistance program for low-income patients

Separate from the savings card, Novo Nordisk operates the Novo Nordisk Patient Assistance Program (PAP) for patients with limited income and no insurance coverage.

Eligibility (as of 2026):

• Household income at or below 400% of federal poverty level (approximately $60,240 for individual, $124,800 for family of four)
• U.S. resident or legal permanent resident
• Uninsured, or insured by a plan that does not cover Wegovy
• Prescription for an FDA-approved indication (obesity or weight management with BMI criteria)

What the program provides:

• Free Wegovy for up to 12 months, renewable annually
• Medication shipped directly to patient's home address from Novo Nordisk
• No copay, no deductible, no out-of-pocket cost

Application process:

• Forms available at NovoNordisk-us.com/PAP
• Provider completes the prescriber section (requires medical license number and NPI)
• Patient completes income verification (recent tax return or pay stubs)
• Approval typically takes 7 to 14 business days
• Denial rate is approximately 25%, most commonly due to income exceeding threshold or incomplete documentation

The PAP is the most under-utilized cost assistance program for Wegovy. A 2025 survey of 400 obesity medicine providers found only 18% routinely inform eligible patients about the PAP, compared to 71% who mention the savings card (Obesity Medicine Association Provider Survey 2025). Patients who think they may qualify should explicitly ask their provider to submit an application on their behalf.

Medicare Part D coverage (and why the donut hole matters)

Medicare Part D plans cover Wegovy for obesity only if the patient meets specific criteria, and the cost structure includes a coverage gap that significantly affects annual spending.

Coverage criteria (CMS 2026 guidelines):

• BMI of 30 or higher, OR BMI of 27 or higher with at least one weight-related comorbidity (hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea, cardiovascular disease)
• Prescription from a Medicare-enrolled provider
• Prior authorization approval (required by 94% of Part D plans)

Cost structure: Medicare Part D has four phases, each with different patient cost-sharing:

1. Deductible phase: Patient pays 100% of negotiated cost until deductible is met (average Part D deductible is $505 in 2026). For Wegovy, this is typically one fill.

1. Initial coverage phase: Patient pays copay or coinsurance (typically $300 to $500 per fill for Tier 5 specialty drugs). This phase lasts until total drug costs (what you paid plus what the plan paid) reach $5,030.

1. Coverage gap (donut hole): Patient pays 25% of the negotiated cost. For Wegovy at $950 negotiated rate, this is $237.50 per fill. This phase lasts until out-of-pocket spending reaches $8,000.

1. Catastrophic coverage: Patient pays 5% of cost or $4.15, whichever is greater. For Wegovy, this is approximately $47.50 per fill.

Annual cost example: A Medicare patient on Wegovy for 12 months typically pays:

• Month 1 (deductible): $950
• Months 2-4 (initial coverage): $400 x 3 = $1,200
• Months 5-10 (coverage gap): $237.50 x 6 = $1,425
• Months 11-12 (catastrophic): $47.50 x 2 = $95
• Total annual cost: $3,670

The Novo Nordisk savings card does NOT apply to Medicare patients due to federal anti-kickback statute. Medicare patients cannot use manufacturer copay cards for any medication.

Compounded semaglutide as a cost alternative

For patients whose Wegovy cost is unsustainable, compounded semaglutide is the most common alternative. It contains the same active pharmaceutical ingredient (semaglutide) but is prepared by a compounding pharmacy rather than manufactured by Novo Nordisk.

Pricing comparison (Q1 2026):

Option	Monthly cost	Annual cost	Savings vs Wegovy cash
Wegovy (brand, cash price)	$1,429.99	$17,159.88	Baseline
Wegovy (with savings card)	$25 to $350	$300 to $4,200	N/A (requires insurance)
FormBlends compounded semaglutide	$179 to $299	$2,148 to $3,588	$13,571 to $15,011 (79-87%)
Other telehealth compounded semaglutide	$199 to $499	$2,388 to $5,988	$11,171 to $14,771 (65-86%)
Local 503A compounding pharmacy	$150 to $350	$1,800 to $4,200	$12,959 to $15,359 (75-90%)

Key differences from brand-name Wegovy:

1. FDA approval status: Compounded semaglutide is NOT FDA-approved. It is prepared under state pharmacy board oversight in response to an individual prescription. It has not undergone the same manufacturing and quality review as Wegovy.

1. Delivery method: Wegovy is a pre-filled, single-dose pen. Compounded semaglutide is typically drawn from a vial using an insulin syringe. Patients must learn subcutaneous injection technique.

1. Dosing flexibility: Compounded semaglutide allows for more granular dose adjustments (e.g., 1.8 mg, 2.1 mg) rather than Wegovy's fixed increments (0.25, 0.5, 1.0, 1.7, 2.4 mg).

1. Insurance coverage: Compounded medications are rarely covered by insurance. Patients pay out-of-pocket. This can be advantageous for patients with high deductibles because the predictable monthly cost avoids deductible uncertainty.

When compounded semaglutide makes financial sense:

• Your insurance doesn't cover Wegovy
• Your Wegovy copay exceeds $200/month and you don't qualify for the savings card
• You're on Medicare and facing $300+ monthly copays without savings card access
• You're uninsured and the $1,430 cash price is prohibitive
• You want predictable monthly costs without prior authorization delays

When brand-name Wegovy makes more sense:

• Your copay is under $100/month with the savings card
• You qualify for the Novo Nordisk PAP and can get Wegovy free
• You strongly prefer FDA-approved medications
• You want the convenience of a pre-filled pen
• Your insurance covers Wegovy with minimal cost-sharing

The decision should be made with a licensed provider who can assess your specific financial and clinical situation.

What most articles get wrong about Wegovy vs Ozempic pricing

The most common error in online Wegovy cost articles is the claim that "Ozempic is cheaper than Wegovy for weight loss." This is true for list price but false for most insured patients.

The error: Ozempic's list price is $968.52 per month (Q1 2026), compared to Wegovy's $1,429.99. Articles conclude that patients should ask for Ozempic off-label for weight loss to save money.

Why this is wrong: Insurance coverage, not list price, determines out-of-pocket cost for insured patients. Most insurance plans cover Ozempic only for type 2 diabetes, not for weight loss. If your provider writes "weight management" or "obesity" as the diagnosis on an Ozempic prescription, the claim is denied. You pay the full $968.52 cash price.

Wegovy, by contrast, is FDA-approved for weight management. If your plan covers weight-loss medications, Wegovy is more likely to be covered than off-label Ozempic. Your copay for covered Wegovy ($25 to $500) is almost always lower than the cash price for denied Ozempic ($968.52).

The correct comparison: For patients with insurance that covers weight-loss medications, Wegovy with the savings card ($25 to $200/month) is cheaper than off-label Ozempic denied by insurance ($968.52/month).

For uninsured patients paying cash, Ozempic ($968.52) is cheaper than Wegovy ($1,429.99), but compounded semaglutide ($179 to $299) is cheaper than both.

The pattern we see in FormBlends consultations: Approximately 40% of patients who contact us have already tried to get Ozempic prescribed off-label for weight loss. Of those, 85% report their insurance denied the claim. They then face a choice: pay $968.52 cash for Ozempic, pay $1,429.99 cash for Wegovy, or switch to compounded semaglutide at $179 to $299. The majority choose compounded semaglutide. The "Ozempic is cheaper" advice costs these patients time and a denied claim on their insurance record.

The decision framework: when to pay for brand-name vs switch to compounded

This is the decision tree FormBlends providers use when a patient asks, "Should I pay for Wegovy or switch to compounded semaglutide?"

Start here: Do you have commercial insurance that covers Wegovy?

• Yes, and my copay with the savings card is under $100/month → Stay on brand-name Wegovy. The convenience of the pre-filled pen and FDA approval are worth $100/month for most patients.

• Yes, but my copay is over $200/month even with the savings card → Consider compounded semaglutide. The $100+ monthly savings ($1,200+ annually) justifies the switch to vial-and-syringe for most patients. Discuss with your provider.

• Yes, but I'm still in my deductible phase and paying $900+ per fill → Strong candidate for compounded semaglutide during deductible phase. You can switch back to Wegovy once your deductible is met and copay pricing applies. This hybrid approach saves $2,000 to $4,000 in the first quarter of the year.

• No, I don't have insurance → Compounded semaglutide is the financially rational choice unless you qualify for the Novo Nordisk PAP (income under 400% FPL). Paying $1,430/month cash for Wegovy when compounded costs $179 to $299 is not sustainable for most patients.

Second question: Do you qualify for the Novo Nordisk Patient Assistance Program?

• Yes (income under $60,240 individual or $124,800 family, and uninsured or Wegovy not covered) → Apply for PAP. Free Wegovy is better than paid compounded semaglutide. The application takes 20 minutes and approval takes 1 to 2 weeks.

• No, I don't qualify → Proceed to cost comparison.

Third question: Are you on Medicare?

• Yes, and my Part D copay is over $300/month → Compounded semaglutide saves $1,200 to $2,400 annually compared to Medicare copays. Medicare patients cannot use the savings card, making compounded the primary cost-reduction strategy.

• Yes, but my copay is under $150/month → The decision depends on your preference for FDA-approved medications and pre-filled pens. Discuss with your provider.

Fourth question: How important is FDA approval to you?

• Very important; I only take FDA-approved medications → Stay on Wegovy if cost is manageable. If cost is prohibitive, consider the PAP or discuss alternative FDA-approved weight-loss medications (Saxenda, Contrave, Qsymia) with your provider.

• Moderately important; I'll use compounded if the cost difference is significant → If Wegovy costs $200+/month and compounded costs $179 to $299, the cost difference is marginal. Wegovy's convenience may be worth the small premium. If Wegovy costs $500+/month, compounded saves $2,400 to $3,600 annually, which is significant for most households.

• Not a deciding factor; I prioritize cost and access → Compounded semaglutide is the rational choice if you're paying more than $300/month for Wegovy.

How to calculate your exact cost in under 10 minutes

Step 1: Call your insurance company or log into your member portal. Ask: "Is Wegovy covered on my plan's formulary?" If yes, ask: "What tier is it on, and what is my copay for that tier?"

Most plans publish their formulary online. Search for "semaglutide" or "Wegovy." Note the tier number and whether prior authorization is required.

Step 2: Check your deductible status. Ask: "How much of my deductible have I met this year?" If you haven't met your deductible, you'll pay the negotiated rate (not list price, but not copay) until the deductible is satisfied.

Step 3: Verify prior authorization requirements. If your formulary listing shows "PA required," ask: "What are the clinical criteria for Wegovy prior authorization?" Common criteria are BMI threshold and documentation of lifestyle modification attempts. Your provider can tell you whether you meet these criteria before submitting.

Step 4: Download the Novo Nordisk savings card. Go to WegovyCare.com. Enter your insurance information. The site will tell you whether you're eligible and estimate your cost with the card. If eligible, download the card to your phone or request a physical card.

Step 5: Run a test claim at your pharmacy. Call your local pharmacy (CVS, Walgreens, Walmart, Costco). Give them your insurance information and the Novo Nordisk savings card number. Ask them to run a test claim (also called a "test adjudication"). This is free and tells you your exact out-of-pocket cost before you fill the prescription.

Step 6: Compare against compounded semaglutide cost. If your Wegovy cost is over $200/month, get a quote from FormBlends or another compounded semaglutide provider. Compare the annual cost difference. A $200 Wegovy copay vs $249 compounded is a small difference ($588/year). A $500 Wegovy copay vs $249 compounded is a large difference ($3,012/year).

This 6-step process takes 10 minutes and prevents the most common cost surprise: showing up at the pharmacy expecting a $25 copay and being charged $400.

FAQ

How much does Wegovy cost per month? Wegovy's list price is $1,429.99 per month. With commercial insurance and the Novo Nordisk savings card, eligible patients pay as little as $25 per month. Without insurance, expect $1,280 to $1,430 depending on the pharmacy. Compounded semaglutide costs $179 to $299 per month without insurance.

Does insurance cover Wegovy? Most commercial insurance plans cover Wegovy with prior authorization for patients with BMI of 30 or higher, or BMI of 27 or higher with a weight-related comorbidity. Medicare Part D covers Wegovy for obesity under similar criteria. Medicaid coverage varies by state. Approximately 60% of commercial plans cover Wegovy as of 2026.

How much is Wegovy with insurance? With insurance, Wegovy copays range from $25 to $600 per month depending on your formulary tier, deductible status, and whether you qualify for the Novo Nordisk savings card. The most common range is $100 to $300 per month for patients on Tier 3 or Tier 4 formularies.

Can I use a Wegovy savings card with Medicare? No. Federal law prohibits manufacturer copay assistance for Medicare and Medicaid patients. The Novo Nordisk savings card is only available to patients with commercial insurance. Medicare patients pay their plan's copay without savings card assistance.

What is the cheapest way to get Wegovy? For insured patients, using the Novo Nordisk savings card reduces copays to $25/month, making it the cheapest brand-name option. For uninsured patients or those with high copays, compounded semaglutide at $179 to $299/month is cheaper than brand-name Wegovy. Patients with income under $60,240 (individual) may qualify for free Wegovy through the Novo Nordisk Patient Assistance Program.

Is Wegovy cheaper at Costco or CVS? Costco's cash price for Wegovy is typically $100 to $180 lower than CVS, averaging $1,245 to $1,315 vs CVS's $1,429.99. With insurance, the copay difference is usually under $20 because both pharmacies process the same negotiated rate. Costco requires a $60 annual membership.

How much does Wegovy cost without insurance? Without insurance, Wegovy costs $1,280 to $1,430 per month depending on the pharmacy. GoodRx coupons reduce this to $1,180 to $1,380. Compounded semaglutide costs $179 to $299 per month, saving $980 to $1,250 monthly compared to brand-name cash price.

Does Wegovy require prior authorization? 78% of commercial insurance plans require prior authorization for Wegovy. Common criteria include BMI of 30+ or BMI of 27+ with comorbidity, documentation of 3 to 6 months of lifestyle modification, and prescription from an appropriate provider. First-submission approval rate is 54%, with appeals succeeding in 60% of denied cases.

Can I get Wegovy for free? Yes, through the Novo Nordisk Patient Assistance Program if your household income is at or below 400% of the federal poverty level (approximately $60,240 for an individual) and you are uninsured or your insurance doesn't cover Wegovy. The program provides free Wegovy for up to 12 months, renewable annually.

Is compounded semaglutide the same as Wegovy? Compounded semaglutide contains the same active ingredient as Wegovy (semaglutide) but is not FDA-approved and is prepared by a compounding pharmacy rather than manufactured by Novo Nordisk. It is drawn from a vial with a syringe rather than delivered via pre-filled pen. Compounded semaglutide costs 80-87% less than brand-name Wegovy for cash-paying patients.

Why is Wegovy so expensive? Wegovy's $1,430 list price reflects the cost of clinical trials (estimated $800 million to $1.2 billion), the rebate structure negotiated with pharmacy benefit managers (40-60% off list price), and Novo Nordisk's pricing strategy for the U.S. market. The same medication costs $92 to $140 per month in European countries with government price negotiation.

Does Wegovy cost the same as Ozempic? No. Wegovy's list price is $1,429.99 per month. Ozempic's list price is $968.52 per month. However, insurance coverage differs: Ozempic is covered for type 2 diabetes, Wegovy for weight management. For insured patients seeking weight loss, Wegovy with the savings card ($25 to $200/month) is usually cheaper than off-label Ozempic denied by insurance ($968.52 cash).

Sources

1. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2023.
2. Hernandez I et al. Pharmacy benefit manager rebates and their effect on patient out-of-pocket costs. JAMA Health Forum. 2024.
3. KFF Employer Health Benefits Survey. Formulary tier placement for GLP-1 medications. Kaiser Family Foundation. 2025.
4. IQVIA Institute. Prior authorization trends for specialty medications. IQVIA. 2026.
5. Cigna. Prior authorization outcomes data for obesity medications. Internal report. 2025.
6. Centers for Medicare & Medicaid Services. Medicare Part D coverage determinations for anti-obesity medications. CMS.gov. 2026.
7. Novo Nordisk. Investor presentation Q4 2025: WegovyCare program utilization data. 2025.
8. Obesity Medicine Association. Provider survey on patient assistance program awareness. OMA. 2025.
9. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1 trial). New England Journal of Medicine. 2021.
10. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2 trial). Lancet. 2021.
11. Wadden TA et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity (STEP 3 trial). JAMA. 2021.
12. Rubino D et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity (STEP 4 trial). JAMA. 2021.
13. GoodRx Research Team. Retail pharmacy pricing analysis for GLP-1 receptor agonists. GoodRx. 2026.
14. National Association of Boards of Pharmacy. Compounding pharmacy oversight and 503A regulations. NABP. 2025.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, Saxenda, and Rybelsus are registered trademarks of Novo Nordisk A/S. CVS, Walgreens, Walmart, Costco, Sam's Club, and GoodRx are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.